Elizabeth B. Lamont
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth B. Lamont has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
James E. Herndon
§CALGB Statistical Center, Duke University Medical Center Durham, North Carolina
2 shared publicationsJane C. Weeks
‡Department of Medicine, Harvard Medical School, Boston, Massachusetts
2 shared publicationsNicholas A. Christakis
†Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts
2 shared publicationsRichard L. Schilsky
††CALGB Central Office, University of Chicago (RLS), Chicago, Illinois
2 shared publicationsRogerio Lilenbaum
**Department of Medicine, Mount Sinai Cancer Center, Miami Beach, Florida
2 shared publications- April F. Eichler
Massachusetts General Hospital Cancer Center, Boston, USA
1 shared publication
Latest Publications
- 27 June 2009
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 95 (3) , 427-431
Utility of administrative claims data for the study of brain metastases: a validation study
In this study, we sought to determine the accuracy with which the International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) diagnosis code for “secondary neoplasm of brain and spinal cord” in health insurance claims measures clinically evident central nervous system (CNS) metastases in patients with non-small cell lung cancer (NSCLC). For 241 consecutive patients with newly diagnosed NSCLC, we compared ICD-9-CM “secondary neoplasm” codes indicating tumor spread to the CNS from institutional billing records to gold-standard chart review to determine: (1) sensitivity, specificity and positive predictive value (PPV) of the site-specific secondary neoplasm code and (2) the accuracy in time of its appearance within billing records compared with the gold standard date of CNS relapse. The occurrence of at least one ICD-9-CM code for brain metastasis (Algorithm 1) had a sensitivity of 100% (95% CI: 100–100%) and PPV of 91% (95% CI: 87–94%). By requiring ≥ 2 codes (Algorithm 2) or ≥ 3 codes (Algorithm 3) for the diagnosis of brain metastasis in claims, specificity and PPV improved, while sensitivity did not drop substantially. The claims-based date of diagnosis was also accurate, with 92% of dates falling within 30 days of the gold standard. ICD-9-CM codes in institutional billing claims reliably documented NSCLC metastases to the CNS. These results suggest that Medicare claims data may be used to evaluate clinical and epidemiological issues related to brain metastases in elderly cancer patients.
- 27 June 2009
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 95 (3) , 427-431
Utility of administrative claims data for the study of brain metastases: a validation study
In this study, we sought to determine the accuracy with which the International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) diagnosis code for “secondary neoplasm of brain and spinal cord” in health insurance claims measures clinically evident central nervous system (CNS) metastases in patients with non-small cell lung cancer (NSCLC). For 241 consecutive patients with newly diagnosed NSCLC, we compared ICD-9-CM “secondary neoplasm” codes indicating tumor spread to the CNS from institutional billing records to gold-standard chart review to determine: (1) sensitivity, specificity and positive predictive value (PPV) of the site-specific secondary neoplasm code and (2) the accuracy in time of its appearance within billing records compared with the gold standard date of CNS relapse. The occurrence of at least one ICD-9-CM code for brain metastasis (Algorithm 1) had a sensitivity of 100% (95% CI: 100–100%) and PPV of 91% (95% CI: 87–94%). By requiring ≥ 2 codes (Algorithm 2) or ≥ 3 codes (Algorithm 3) for the diagnosis of brain metastasis in claims, specificity and PPV improved, while sensitivity did not drop substantially. The claims-based date of diagnosis was also accurate, with 92% of dates falling within 30 days of the gold standard. ICD-9-CM codes in institutional billing claims reliably documented NSCLC metastases to the CNS. These results suggest that Medicare claims data may be used to evaluate clinical and epidemiological issues related to brain metastases in elderly cancer patients.
- 1 March 2008
- Published by Wolters Kluwer Health in Medical Care
- Vol. 46 (3) , 303-308
Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants
Background: Because the elderly are underrepresented on clinical trials, physicians have few sources of information to estimate the risks (ie, toxicities) and benefits of chemotherapy administration to the elderly. Objective: Our goal was to determine whether the standard measures of toxicity used in clinical trials could be captured from observational Medicare claims data. Methods: We identified 175 elderly clinical trial patients treated on 2 Cancer and Leukemia Group B (CALGB) trials (9344, adjuvant breast study and 9730, advanced lung cancer study) and merged participants’ CALGB data with their Medicare data. From CALGB data, we identified the most frequent Extended Clinical Toxicity Critieria grade III/IV toxicities. We reviewed diagnostic and procedure codes from Medicare manuals, developed algorithms to measure the toxicities, and then finalized the algorithms after empiric review of patients’ codes. We compared results of Medicare algorithms to gold standard CALGB toxicity information to calculate test characteristics. Results: CALGB data documented that 15 grade III/IV chemotherapy-related toxicities occurred in ≥3% of the 175 patients: white blood cell, hemoglobin, platelets, anorexia, nausea, vomiting, diarrhea, stomatitis, sensory neuropathy, motor neuropathy, motor or sensory neuropathy, dyspnea, hyperglycemia, infection, and malaise. Vomiting was the only toxicity identified by the Medicare-based algorithm with a sensitivity, specificity, and area under the receiver operator curve of ≥80%. Conclusions: The results of this preliminary study suggest that Medicare diagnostic and procedure codes may be of only limited value in measuring clinically significant chemotherapy-related toxicities in elderly Medicare beneficiaries. Future research includes confirming these findings in a larger and more diverse sample.
- 1 March 2008
- Published by Wolters Kluwer Health in Medical Care
- Vol. 46 (3) , 303-308
Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants
Background: Because the elderly are underrepresented on clinical trials, physicians have few sources of information to estimate the risks (ie, toxicities) and benefits of chemotherapy administration to the elderly. Objective: Our goal was to determine whether the standard measures of toxicity used in clinical trials could be captured from observational Medicare claims data. Methods: We identified 175 elderly clinical trial patients treated on 2 Cancer and Leukemia Group B (CALGB) trials (9344, adjuvant breast study and 9730, advanced lung cancer study) and merged participants’ CALGB data with their Medicare data. From CALGB data, we identified the most frequent Extended Clinical Toxicity Critieria grade III/IV toxicities. We reviewed diagnostic and procedure codes from Medicare manuals, developed algorithms to measure the toxicities, and then finalized the algorithms after empiric review of patients’ codes. We compared results of Medicare algorithms to gold standard CALGB toxicity information to calculate test characteristics. Results: CALGB data documented that 15 grade III/IV chemotherapy-related toxicities occurred in ≥3% of the 175 patients: white blood cell, hemoglobin, platelets, anorexia, nausea, vomiting, diarrhea, stomatitis, sensory neuropathy, motor neuropathy, motor or sensory neuropathy, dyspnea, hyperglycemia, infection, and malaise. Vomiting was the only toxicity identified by the Medicare-based algorithm with a sensitivity, specificity, and area under the receiver operator curve of ≥80%. Conclusions: The results of this preliminary study suggest that Medicare diagnostic and procedure codes may be of only limited value in measuring clinically significant chemotherapy-related toxicities in elderly Medicare beneficiaries. Future research includes confirming these findings in a larger and more diverse sample.
- 1 December 2005
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 8 (supplement) , S12-12
A Demographic and Prognostic Approach to Defining the End of Life
Studies examining individuals' preferences reflect a broad consensus that the end of life is a period during which medical care should be different from that in other periods in patients' lives. More specifically, patients, families, and health care providers believe that medical care during this unique period should be home-based and focused on ameliorating patient symptoms through minimally invasive means rather than hospital-based acute care, and focused on extending life through invasive approaches. Of great concern is that other, empirical research shows that there is a large disparity between these preferred types of medical care at the end of life and the actual patterns of medical care that is observed before death, with most patients dying in acute-care hospitals while receiving invasive therapies. Without prospective recognition of this period, medical care cannot be appropriately changed. Existing research suggests that there are few clinical tools available to health care providers to aid in making prognostic estimates. Opportunities for future research include efforts to improve the prospective identification of the end of life and communication about the end of life. Specifically, development of valid and reliable predictive algorithms to help patients, families, and health care providers to identify the beginning of the end of life would be welcomed and should ideally be focused at the population level to ensure wide applicability. Similarly, research that works to improve communication between patients and health care providers on the matter of prognosis is also needed.
- 1 December 2005
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 8 (supplement) , S12-12
A Demographic and Prognostic Approach to Defining the End of Life
Studies examining individuals' preferences reflect a broad consensus that the end of life is a period during which medical care should be different from that in other periods in patients' lives. More specifically, patients, families, and health care providers believe that medical care during this unique period should be home-based and focused on ameliorating patient symptoms through minimally invasive means rather than hospital-based acute care, and focused on extending life through invasive approaches. Of great concern is that other, empirical research shows that there is a large disparity between these preferred types of medical care at the end of life and the actual patterns of medical care that is observed before death, with most patients dying in acute-care hospitals while receiving invasive therapies. Without prospective recognition of this period, medical care cannot be appropriately changed. Existing research suggests that there are few clinical tools available to health care providers to aid in making prognostic estimates. Opportunities for future research include efforts to improve the prospective identification of the end of life and communication about the end of life. Specifically, development of valid and reliable predictive algorithms to help patients, families, and health care providers to identify the beginning of the end of life would be welcomed and should ideally be focused at the population level to ensure wide applicability. Similarly, research that works to improve communication between patients and health care providers on the matter of prognosis is also needed.
- Open Access
- 20 July 2005
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 97 (14) , 1080-1083
Criterion Validity of Medicare Chemotherapy Claims in Cancer and Leukemia Group B Breast and Lung Cancer Trial Participants
To determine the accuracy with which Medicare claims data measure chemotherapy use in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We compared gold-standard clinical trial data for 175 elderly cancer patients treated in two Cancer and Leukemia Group B (CALGB) breast and lung cancer trials (i.e., 45 from trial 9344 and 130 from trial 9730) with contemporaneous ambulatory and in-patient Medicare health insurance claims data from Centers for Medicare and Medicaid Services (CMS). The breast trial participants studied were those elderly enrolled between 1995 and 1997 and treated with doxorubicin and cyclophosphamide or this combination with paclitaxel. The lung trial participants studied were those elderly enrolled between 1998 and 2000 and treated with paclitaxel and carboplatin or paclitaxel alone. Comparing CALGB data with Medicare claims, we found the crude sensitivity for chemotherapy administration was 93% (95% confidence interval [CI] = 88% to 96%). Individual chemotherapy agents had similarly high sensitivities, ranging from 81% (95% CI = 70% to 89%) for carboplatin to 91% (95% CI = 79% to 98%) for cyclophosphamide. Agent-specific specificities were 100%. CMS data reliably captured repeat administration of chemotherapy to within one cycle. Administrative Medicare claims data appear to be a valid source of information for chemotherapy administered to elderly Medicare beneficiaries with cancer.
- 20 July 2005
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 97 (14) , 1080-1083
Open AccessCriterion Validity of Medicare Chemotherapy Claims in Cancer and Leukemia Group B Breast and Lung Cancer Trial Participants
To determine the accuracy with which Medicare claims data measure chemotherapy use in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We compared gold-standard clinical trial data for 175 elderly cancer patients treated in two Cancer and Leukemia Group B (CALGB) breast and lung cancer trials (i.e., 45 from trial 9344 and 130 from trial 9730) with contemporaneous ambulatory and in-patient Medicare health insurance claims data from Centers for Medicare and Medicaid Services (CMS). The breast trial participants studied were those elderly enrolled between 1995 and 1997 and treated with doxorubicin and cyclophosphamide or this combination with paclitaxel. The lung trial participants studied were those elderly enrolled between 1998 and 2000 and treated with paclitaxel and carboplatin or paclitaxel alone. Comparing CALGB data with Medicare claims, we found the crude sensitivity for chemotherapy administration was 93% (95% confidence interval [CI] = 88% to 96%). Individual chemotherapy agents had similarly high sensitivities, ranging from 81% (95% CI = 70% to 89%) for carboplatin to 91% (95% CI = 79% to 98%) for cyclophosphamide. Agent-specific specificities were 100%. CMS data reliably captured repeat administration of chemotherapy to within one cycle. Administrative Medicare claims data appear to be a valid source of information for chemotherapy administered to elderly Medicare beneficiaries with cancer.
- Open Access
- 16 September 2003
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 95 (18) , 1370-1375
Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Background: Prior research has suggested that patients who travel out of their neighborhood for elective care from specialized medical centers may have better outcomes than local patients with the same illnesses who are treated at the same centers. We hypothesized that this phenomenon, often called “referral bias” or “distance bias,” may also be evident in curative-intent cancer trials at specialized cancer centers. Methods: We evaluated associations between overall survival and progression-free survival and the distance from the patient residence to the treating institution for 110 patients treated on one of four phase II curative-intent chemoradiotherapy protocols for locoregionally advanced squamous cell cancer of the head and neck conducted at the University of Chicago over 7 years. Results: Using Cox regression that adjusted for standard patient-level disease and demographic factors and neighborhood-level economic factors, we found a positive association between the distance patients traveled from their residence to the treatment center and survival. Patients who lived more than 15 miles from the treating institution had only one-third the hazard of death of those living closer (hazard ratio [HR] = 0.32, 95% confidence interval [CI] = 0.12 to 0.84). Moreover, with every 10 miles that a patient traveled for care, the hazard of death decreased by 3.2% (HR = 0.97, 95% CI = 0.94 to 0.99). Similar results were obtained for progression-free survival. Conclusion: Results of phase II curative-intent clinical trials in oncology that are conducted at specialized cancer centers may be confounded by patient travel distance, which captures prognostic significance beyond cancer stage, performance status, and wealth. More work is needed to determine what unmeasured factors travel distance is mediating.
- 16 September 2003
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 95 (18) , 1370-1375
Open AccessIs Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Background: Prior research has suggested that patients who travel out of their neighborhood for elective care from specialized medical centers may have better outcomes than local patients with the same illnesses who are treated at the same centers. We hypothesized that this phenomenon, often called “referral bias” or “distance bias,” may also be evident in curative-intent cancer trials at specialized cancer centers. Methods: We evaluated associations between overall survival and progression-free survival and the distance from the patient residence to the treating institution for 110 patients treated on one of four phase II curative-intent chemoradiotherapy protocols for locoregionally advanced squamous cell cancer of the head and neck conducted at the University of Chicago over 7 years. Results: Using Cox regression that adjusted for standard patient-level disease and demographic factors and neighborhood-level economic factors, we found a positive association between the distance patients traveled from their residence to the treatment center and survival. Patients who lived more than 15 miles from the treating institution had only one-third the hazard of death of those living closer (hazard ratio [HR] = 0.32, 95% confidence interval [CI] = 0.12 to 0.84). Moreover, with every 10 miles that a patient traveled for care, the hazard of death decreased by 3.2% (HR = 0.97, 95% CI = 0.94 to 0.99). Similar results were obtained for progression-free survival. Conclusion: Results of phase II curative-intent clinical trials in oncology that are conducted at specialized cancer centers may be confounded by patient travel distance, which captures prognostic significance beyond cancer stage, performance status, and wealth. More work is needed to determine what unmeasured factors travel distance is mediating.